Apimeds Pharmaceuticals US readies Delaware Court of Chancery action over Inscobee board takeover attempt

Reuters

Mar 24

Apimeds Pharmaceuticals US readies <a href="https://laohu8.com/S/VMM">Delaware</a> Court of Chancery action over Inscobee board takeover attempt

Apimeds Pharmaceuticals US said Inscobee and its subsidiary Apimeds filed an amended Schedule 13D asserting they removed four directors and installed three replacements by written consent.
The company said the consent used 6,416,365 shares subject to an irrevocable proxy and was executed without authorization.
MindWave and Apimeds Pharmaceuticals US plan to file an emergency action in the Delaware Court of Chancery under 8 Del. C. § 225 seeking a declaration that the consent is void and requesting a temporary restraining order.
Apimeds Pharmaceuticals US said it also engaged legal counsel in South Korea to pursue remedies under Korean law related to Inscobee’s actions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2621906268"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621906268\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621906268?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621906268","market":"nz","top_or_hot":-1,"title":"Apimeds Pharmaceuticals US readies Delaware Court of Chancery action over Inscobee board takeover attempt","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Apimeds Pharmaceuticals US readies <a href=\"https://laohu8.com/S/VMM\">Delaware</a> Court of Chancery action over Inscobee board takeover attempt\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Apimeds Pharmaceuticals US said Inscobee and its subsidiary Apimeds filed an amended Schedule 13D asserting they removed four directors and installed three replacements by written consent.\n        </li>\n<li>\n          The company said the consent used 6,416,365 shares subject to an irrevocable proxy and was executed without authorization.\n        </li>\n<li>\n          MindWave and Apimeds Pharmaceuticals US plan to file an emergency action in the Delaware Court of Chancery under 8 Del. C. § 225 seeking a declaration that the consent is void and requesting a temporary restraining order.\n        </li>\n<li>\n          Apimeds Pharmaceuticals US said it also engaged legal counsel in South Korea to pursue remedies under Korean law related to Inscobee’s actions.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apimeds Pharmaceuticals US readies Delaware Court of Chancery action over Inscobee board takeover attempt</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApimeds Pharmaceuticals US readies Delaware Court of Chancery action over Inscobee board takeover attempt\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-24 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Apimeds Pharmaceuticals US readies <a href=\"https://laohu8.com/S/VMM\">Delaware</a> Court of Chancery action over Inscobee board takeover attempt\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Apimeds Pharmaceuticals US said Inscobee and its subsidiary Apimeds filed an amended Schedule 13D asserting they removed four directors and installed three replacements by written consent.\n        </li>\n<li>\n          The company said the consent used 6,416,365 shares subject to an irrevocable proxy and was executed without authorization.\n        </li>\n<li>\n          MindWave and Apimeds Pharmaceuticals US plan to file an emergency action in the Delaware Court of Chancery under 8 Del. C. § 225 seeking a declaration that the consent is void and requesting a temporary restraining order.\n        </li>\n<li>\n          Apimeds Pharmaceuticals US said it also engaged legal counsel in South Korea to pursue remedies under Korean law related to Inscobee’s actions.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APUS","symbol_name":"Apimeds Pharmaceutical  U.S, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDLb7n3X4:1","article_id":"2621906268","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621906268","pubTimestamp":1774355451,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Apimeds Pharmaceuticals US said Inscobee and its subsidiary Apimeds filed an amended Schedule 13D asserting they removed four directors and installed three replacements by written consent.The company said the consent used 6,416,365 shares subject to an irrevocable proxy and was executed without authorization.MindWave and Apimeds Pharmaceuticals US plan to file an emergency action in the Delaware Court of Chancery under 8 Del. C. § 225 seeking a declaration that the consent is void and requesting a temporary restraining order.Apimeds Pharmaceuticals US said it also engaged legal counsel in South Korea to pursue remedies under Korean law related to Inscobee’s actions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APUS":"Apimeds Pharmaceutical  U.S, Inc.","BK4139":"生物科技"},"translate_title":"Apimeds Pharmaceuticals US准备就Inscobee董事会收购尝试向特拉华州衡平法院提起诉讼","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APUS":0.9},"content_text":"Apimeds Pharmaceuticals US readies Delaware Court of Chancery action over Inscobee board takeover attempt\n    \n\n\n          Apimeds Pharmaceuticals US said Inscobee and its subsidiary Apimeds filed an amended Schedule 13D asserting they removed four directors and installed three replacements by written consent.\n        \n\n          The company said the consent used 6,416,365 shares subject to an irrevocable proxy and was executed without authorization.\n        \n\n          MindWave and Apimeds Pharmaceuticals US plan to file an emergency action in the Delaware Court of Chancery under 8 Del. C. § 225 seeking a declaration that the consent is void and requesting a temporary restraining order.\n        \n\n          Apimeds Pharmaceuticals US said it also engaged legal counsel in South Korea to pursue remedies under Korean law related to Inscobee’s actions.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}